Is Adagrasib Bangladesh Everest expensive?

Adagrasib (Adagrasib) is a highly selective and potent oral small molecule inhibitor of KRASG12C. Adagarasib is specifically designed to address the challenge of KRAS 12C and is optimized to sustain on-target inhibition, a property that is important for treating KRAS 12C mutant cancers because KRAS 12C protein regenerates every 24-48 hours. Adagarasib has been clinically shown to be a CNS penetrating agent, which may be important given that CNS metastases frequently occur in NSCLC and result in poor prognosis.

In the United States, The U.S. Food and Drug Administration (FDA) placed adagrasiib under accelerated approval review (Subpart H), which allows approval of drugs that treat serious conditions and that fill an unmet medical need based on surrogate endpoints. Adagarasib was reviewed under the FDA Real-Time Oncology Review (RTOR) pilot program, which was designed to explore a more efficient review process to ensure safe and effective treatments are delivered to patients sooner. Adagrasibis indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer determined to have a KRASG12C mutation as determined by an FDA-approved test and who have received at least one prior systemic therapy.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas, including Bangladesh Everest Pharmaceuticals. For more drug information and specific prices, please consult Yaode’s medical consultant.